Denali Therapeutics Inc. (DNLI) Operating Margin
- Operating margin · 12 months: Value -15058.19%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -15058.19% | Operating income / revenue. Period ending 2026-06-30. $-542.70M ÷ $3.60M × 100 ≈ -15058.19% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -542.70M USD | Operating Income (Loss) |
| Revenue | 3.60M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 400.72M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-542.70M | $3.60M | (m) | $400.72M | (m) | -15058.19% |
| 2026-03-31 | $-547.12M | (m) | (m) | $406.40M | (m) | (m) |
| 2025-12-31 | $-555.34M | $0.00 | (m) | $418.78M | (m) | (m) |
| 2025-09-30 | $-547.82M | (m) | (m) | $420.66M | (m) | (m) |
| 2025-06-30 | $-533.58M | (m) | (m) | $416.95M | (m) | (m) |
| 2025-03-31 | $-515.21M | (m) | (m) | $405.65M | (m) | (m) |
| 2024-12-31 | $-487.34M | $0.00 | (m) | $396.44M | (m) | (m) |
| 2024-09-30 | $-490.07M | $0.00 | (m) | $404.46M | (m) | (m) |
| 2024-06-30 | $-480.68M | $1.27M | (m) | $395.95M | (m) | -37938.04% |
| 2024-03-31 | $-193.60M | $295.39M | (m) | $402.08M | (m) | -65.54% |
| 2023-12-31 | $-196.70M | $330.53M | (m) | $423.88M | (m) | -59.51% |
| 2023-09-30 | $-169.47M | $340.79M | (m) | $408.18M | (m) | -49.73% |
| 2023-06-30 | $-163.16M | $339.71M | (m) | $406.23M | (m) | -48.03% |
| 2023-03-31 | $-395.06M | $98.06M | (m) | $401.45M | (m) | -402.86% |
| 2022-12-31 | $-340.74M | $105.06M | (m) | $358.73M | (m) | -324.32% |
| 2022-09-30 | $-312.52M | $107.32M | (m) | $334.50M | (m) | -291.21% |
| 2022-06-30 | $-290.63M | $112.42M | (m) | $318.27M | (m) | -258.52% |
| 2022-03-31 | $-291.03M | $82.88M | (m) | $291.24M | (m) | -351.16% |
| 2021-12-31 | $-295.75M | $48.66M | (m) | $265.35M | (m) | -607.83% |
| 2021-09-30 | $25.45M | $352.95M | (m) | $252.22M | (m) | 7.21% |
| 2021-06-30 | $50.92M | $357.06M | (m) | $234.37M | (m) | 14.26% |
| 2021-03-31 | $51.47M | $339.93M | (m) | $221.81M | (m) | 15.14% |
| 2020-12-31 | $62.72M | $335.56M | (m) | $212.62M | (m) | 18.69% |
| 2020-09-30 | $-239.12M | $23.71M | (m) | $209.42M | (m) | -1008.43% |
| 2020-06-30 | $-229.16M | $27.83M | (m) | $208.26M | (m) | -823.36% |
| 2020-03-31 | $-230.64M | $26.12M | (m) | $207.00M | (m) | -883.05% |
| 2019-12-31 | $-213.18M | $26.68M | (m) | $193.38M | (m) | -799.10% |
| 2019-09-30 | $-80.70M | $147.68M | (m) | $181.74M | (m) | -54.65% |
| 2019-06-30 | $-68.51M | $135.27M | (m) | $159.52M | (m) | -50.65% |
| 2019-03-31 | $-63.13M | $132.72M | (m) | $159.77M | (m) | -47.57% |
| 2018-12-31 | $-46.37M | $129.16M | (m) | $143.18M | (m) | -35.90% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-90.14M | $0.00 | (m) | $74.46M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-87.43M | $0.00 | (m) | $75.70M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |